|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ben Amar J, Ben Safta B, Zaibi H, Dhahri
B, Baccar MA and Azzabi S: Prognostic factors of advanced stage
non-small-cell lung cancer. Tunis Med. 94:360–367. 2016.PubMed/NCBI
|
|
4
|
Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ,
Zhao D and Shan L: Vasohibin-1 expression detected by
immunohistochemistry correlates with prognosis in non-small cell
lung cancer. Med Oncol. 31:9632014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bice T, Li G, Malinchoc M, Lee AS and
Gajic O: Incidence and risk factors of recurrent acute lung injury.
Crit Care Med. 39:1069–1073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rubenfeld GD, Caldwell E, Peabody E,
Weaver J, Martin DP, Neff M, Stern EJ and Hudson LD: Incidence and
outcomes of acute lung injury. N Engl J Med. 353:1685–1693. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matthay MA, Robriquet L and Fang X:
Alveolar epithelium: Role in lung fluid balance and acute lung
injury. Proc Am Thorac Soc. 2:pp. 206–213. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng MY, Liao QJ and Su Q: Advance in
research on uPAR and tumor. Int J Pathol Clin Med. 31:49–53.
2011.(In Chinese).
|
|
10
|
Andres SA, Edwards AB and Wittliff JL:
Expression of urokinase-type plasminogen activator (uPA), its
receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas
and their clinical relevance. J Clin Lab Anal. 26:93–103. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thummarati P, Wijitburaphat S, Prasopthum
A, Menakongka A, Sripa B, Tohtong R and Suthiphongchai T: High
level of urokinase plasminogen activator contributes to
cholangiocarcinoma invasion and metastasis. World J Gastroenterol.
18:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urban P, Vuaroqueaux V, Labuhn M,
Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U
and Eppenberger-Castori S: Increased expression of urokinase-type
plasminogen activator mRNA determines adverse prognosis in
ErbB2-positive primary breast cancer. J Clin Oncol. 24:4245–4253.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mekkawy AH, Morris DL and Pourgholami MH:
HAX1 augments cell proliferation, migration, adhesion, and invasion
induced by urokinase-type plasminogen activator receptor. J Oncol.
2012:9507492012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guyot P, Ades AE, Ouwens MJ and Welton NJ:
Enhanced secondary analysis of survival data: Reconstructing the
data from published Kaplan-Meier survival curves. BMC Med Res
Methodol. 12:92012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Panic N, Leoncini E, de Belvis G,
Ricciardi W and Boccia S: Evaluation of the endorsement of the
preferred reporting items for systematic reviews and meta-analysis
(PRISMA) statement on the quality of published systematic review
and meta-analyses. PLoS One. 8:e831382013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Almasi CE, Høyer-Hansen G, Christensen IJ,
Danø K and Pappot H: Prognostic impact of liberated domain I of the
urokinase plasminogen activator receptor in squamous cell lung
cancer tissue. Lung Cancer. 48:349–355. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Almasi CE, Høyer-Hansen G, Christensen IJ
and Pappot H: Prognostic significance of urokinase plasminogen
activator receptor and its cleaved forms in blood from patients
with non-small cell lung cancer. APMIS. 117:755–761. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Almasi CE, Christensen IJ, Høyer-Hansen G,
Danø K, Pappot H, Dienemann H and Muley T: Urokinase receptor forms
in serum from non-small cell lung cancer patients: Relation to
prognosis. Lung Cancer. 74:510–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blumenschein GR Jr, Reck M, Fossella F,
Stewart DJ, Lathia C and Peña C: Plasma biomarkers correlating with
clinical outcome in a phase II study of sorafenib in advanced
NSCLC. Cancer Biomark. 10:287–298. 2011–2012. View Article : Google Scholar
|
|
21
|
Su CY, Liu YP, Yang CJ, Lin YF, Chiou J,
Chi LH, Lee JJ, Wu AT, Lu PJ, Huang MS and Hsiao M: Plasminogen
activator inhibitor-2 plays a leading prognostic role among
protease families in non-small cell lung cancer. PLoS One.
10:e01334112015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pappot H: The plasminogen activation
system in lung cancer-with special reference to the prognostic role
in ‘non-small cell lung cancer’. APMIS Suppl. 92:1–29.
1999.PubMed/NCBI
|
|
23
|
Offersen BV, Pfeiffer P, Andreasen P and
Overgaard J: Urokinase plasminogen activator and plasminogen
activator inhibitor type-1 in nonsmall-cell lung cancer: Relation
to prognosis and angiogenesis. Lung Cancer. 56:43–50. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pappot H, Pedersen AN, Brünner N and
Christensen IJ: The complex between urokinase (uPA) and its type-1
inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to
prognosis. Lung Cancer. 51:193–200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pedersen H, Grøndahl-Hansen J, Francis D,
Osterlind K, Hansen HH, Danø K and Brünner N: Urokinase and
plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Cancer Res. 54:120–123. 1994.PubMed/NCBI
|
|
26
|
Salden M, Splinter TA, Peters HA, Look MP,
Timmermans M, van Meerbeeck JP and Foekens JA: The urokinase-type
plasminogen activator system in resected non-small-cell lung
cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol.
11:327–332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Werle B, Kotzsch M, Lah TT, Kos J,
Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W,
Luther T, et al: Cathepsin B, plasminogenactivator-inhibitor
(PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic
factors for patients with non-small cell lung cancer. Anticancer
Res. 24:4147–4161. 2004.PubMed/NCBI
|
|
28
|
Li Y, Shen Y, Miao Y, Luan Y, Sun B and
Qiu X: Co-expression of uPAR and CXCR4 promotes tumor growth and
metastasis in small cell lung cancer. Int J Clin Exp Pathol.
7:3771–3780. 2014.PubMed/NCBI
|
|
29
|
Thielemann A, Baszczuk A, Kopczyński P and
Kopczyński Z: High concentration of urokinase-type plasminogen
activator receptor in the serum of women with primary breast
cancer. Contemp Oncol (Pozn). 17:440–445. 2013.PubMed/NCBI
|
|
30
|
Pulukuri SM, Gorantla B, Dasari VR, Gondi
CS and Rao JS: Epigenetic upregulation of urokinase plasminogen
activator promotes the tropism of mesenchymal stem cells for tumor
cells. Mol Cancer Res. 8:1074–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Bock CE and Wang Y: Clinical
significance of urokinase-type plasminogen activator receptor
(uPAR) expression in cancer. Med Res Rev. 24:13–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiang SP, Cabrera RM and Segall JE: Tumor
cell intravasation. Am J Physiol Cell Physiol. 311:C1–C14. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Noh H, Hong S and Huang S: Role of
urokinase receptor in tumor progression and development.
Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Montuori N, Pesapane A, Rossi FW, Giudice
V, De Paulis A, Selleri C and Ragno P: Urokinase type plasminogen
activator receptor (uPAR) as a new therapeutic target in cancer.
Transl Med UniSa. 15:15–21. 2016.PubMed/NCBI
|
